This week in therapeutics




Licensing status

Publication and contact information


Alzheimer's disease (AD)

Ryanodine receptor 1 (RyR1); RyR2

Studies in mice suggest ryanodine receptor agonists could be useful for treating AD. In a mouse model of hereditary AD, ryanodine receptor-mediated calcium release and hippocampal Ryr1 and Ryr2 levels were lower than those in normal mice. In mouse brain slices, knockdown of Ryr1 and Ryr2 decreased activity-dependent calcium release and neuronal activity compared with no knockdown. Next steps could include testing the effects of moderate ryanodine receptor agonists on cognitive function in mouse models of AD.

SciBX 6(37); doi:10.1038/scibx.2013.1032
Published online Sept. 26, 2013

Patent and licensing status undisclosed

Wu, B. et al. Proc. Natl. Acad. Sci. USA; published online Aug. 5, 2013;
Contact: Jie Shen, Harvard Medical School, Boston, Mass.